| Followers | 9 |
| Posts | 120 |
| Boards Moderated | 0 |
| Alias Born | 02/20/2024 |
Thursday, March 13, 2025 1:30:35 PM
I'm just wondering.
Media > News releases > News release
Merck Unveils New Facility to Increase Vaccine Production Capacity
Save
March 11, 2025 6:45 am ET
Opening highlights effort to expand U.S. manufacturing through a $1 billion investment
DURHAM, N.C.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.
This expansion of our Durham plant is a crucial component of the more than $12 billion Merck has invested toward U.S. capital investment since 2018 focused on expanding domestic manufacturing and research and development capabilities and creating new jobs in the U.S., with another $8 billion of U.S. capital investment expected by 2028.
"Expanding our state-of-the-art manufacturing facility in Durham marks a significant milestone in our efforts to strengthen our production and manufacturing capabilities in the U.S.," said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. "The cutting-edge technologies employed here empower our workforce and underscore our leadership in innovation to support patients everywhere."
The state-of-the-art manufacturing facility leverages best practices and learnings from across the Merck Manufacturing Division network as well as new technical and digital capabilities including data analytics, generative AI, 3D printing and a training center equipped with a digital twin – a virtual model of the shop floor manufacturing process systems – to accelerate new employee training and simulate process changes before they are implemented.
“This level of investment and commitment speaks so powerfully to the work we do here in Durham,” said Amanda Taylor, vice president and plant manager at the Merck Manufacturing Division site in Durham. “To see the pride and the energy of the people who work here and are helping drive this evolution in our capabilities is just phenomenal.”
Please visit the Merck media library for images and b-roll of the new Durham facility.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Media Contacts:
Ned Ehrbar
(646) 593-1669
ned.ehrbar@merck.com
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Damini Chokshi
(732) 594-1577
damini.chokshi@merck.com
Source: Merck & Co., Inc.
Multimedia
Merck Logo Horizontal Teal Grey RGB (211 KB)
opt-in primary image
Sign up for email alerts
Unsubscribe from email alerts
Related links
related content image #1
Company Statements
Read our latest company statements.
related content image #2
Media library
Access videos, logos, photos, and infographics.
related content image #3
About Merck
We are committed to providing leading innovations for today and the future that save and improve lives around the world.
Connect with us on social
social icon
social icon
social icon
social icon
social icon
For patients and health care professionals
MerckHelps
Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients.
Merck Access Program
Information about insurance coverage and financial assistance options for eligible patients.
Clinical trials
Learn about our clinical trials and find available studies.
Merck Manuals
Medical information source covering thousands of topics in all fields of medicine.
Sustainability
Impact Report
Reporting on our commitment to operating responsibly to benefit society.
Merck for Mothers
An initiative to create a world where no woman has to die giving life.
About Merck
Merck Animal Health
The global animal health business unit of Merck.
Health Plan - Transparency in Coverage
In compliance with the Consolidated Appropriations Act, learn more about our health plan’s pricing information.
Contact Us
If you have a question or need more information about us, find out who you should contact.
Forward-looking statementCookie policyCookie PreferencesPrivacyTransparency disclosureTerms of useAccessibilitySitemapConsumer Health Data Privacy PolicyYour Privacy Choices
Copyright © 2025 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon
View Privacy Shield Verification Status
View APEC CBPR Privacy Certification Status
Recent NWBO News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
Alliance Creative Group (ACGX) Announces the Launch of the Alliance Creative Ai Agency and ACGX.AI • ACGX • Dec 15, 2025 8:30 AM
One World Products (to become Isiah Enterprises) Targets December Operational Breakeven; 250,000+ Pounds of Pelletized Rubber Shipped • OWPC • Dec 10, 2025 11:24 AM
Growing Momentum Signals Opportunity as Explorers Shift Toward Production, Reveal Substantial Value • LFLRF • Dec 10, 2025 9:00 AM
Branded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New Leadership • BLEG • Dec 10, 2025 9:00 AM
Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing • BLO • Dec 9, 2025 8:45 AM
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival • AVAI • Dec 9, 2025 8:00 AM
